Radiopharm Theranostics RADX
NASDAQ RADX
$1.42 -0.06 (-4.05%)
At close: Oct 2, 2026 · 4:00 PM EDT

Radiopharm Theranostics (RADX) Income from Non-Controlling Interests (2023 - 2026)

Updated

Radiopharm Theranostics (RADX) reported Income from Non-Controlling Interests of -$12,234 for FY2026 (year ended Jun 30, 2026), compared with -$1.64 million in FY2025.

Analysis

Radiopharm Theranostics (RADX) Income from Non-Controlling Interests (2023 - 2026) Analysis & Trends

Dating back to FY2023, Radiopharm Theranostics' Income from Non-Controlling Interests record includes 4 fiscal years.

  • According to Business Quant data, Income from Non-Controlling Interests came in at -$1.64 million in FY2025, -$1.96 million in FY2024 and -$162,529 in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn -
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn -
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 3.00 Mn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -2.00 Mn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -7.00 Mn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 1.00 Mn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn -
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 10.00 Mn
10 Radiopharm Theranostics 5.03 Bn 5.00 Bn 186,835.86 -1.28 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1.28 Mn
Jun 30, 2025 -1.64 Mn
Jun 30, 2024 -1.96 Mn
Jun 30, 2023 -162,529.00
API Access

Radiopharm Theranostics Income from Non-Controlling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=RADX&period=max&api_key=YOUR_API_KEY